Workflow
Aurisco(605116)
icon
Search documents
奥锐特:关于奥锐特药业股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告
2024-04-28 07:51
关于奥锐特药业股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 | | | 二、非经营性资金占用及其他关联资金往来情况汇总表 …………第 3一3 页 let 您可提用手机 "扫一扫" (规进入"注册在平台现在申请有载全讯网的会计网项方乐出页, 您可提用手机 "扫一扫" (规进人"注册会计算行业定一监管平台(http://www.m20864 非经营性资金占用及其他关联资金往来情况的 专项审计说明 委托单位:奥锐特药业股份有限公司 审计单位:天健会计师事务所(特殊普通合伙) 联系电话:0571-89722900 发 二、管理层的责任 奥锐特公司管理层的责任是提供真实、合法、完整的相关资料,按照《上市 公司监管指引第8号 -- 上市公司资金往来、对外担保的监管要求》(证监会公 告〔2022〕26 号)和《上海证券交易所上市公司自律监管指南第2 号 -- 业务 办理(2023年12月修订)》(上证函〔2023〕3870 号)的规定编制汇总表,并保 证其内容真实、准确、完整,不存在虚假记载、误导性陈述或重大遗漏。 诚信 公正 务实 专业 第 1 页 共 ...
奥锐特(605116) - 2023 Q4 - 年度财报
2024-04-28 07:47
Financial Performance - The total revenue for the cardiovascular raw materials segment reached ¥300,413,911.15, representing a 26.94% increase compared to the previous year[21]. - The gross profit margin for the oncology raw materials segment was 43.33%, with a revenue increase of 73.63% year-over-year[21]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in the last fiscal year, representing a growth of 20% year-over-year[133]. - The company reported a revenue of 1.5 billion RMB for the fiscal year 2023, representing a year-over-year growth of 15%[136]. - The company has set a revenue guidance for the next fiscal year at 1.8 billion RMB, which reflects an expected growth of 20%[136]. - The company provided guidance for the next fiscal year, projecting revenue growth of 25% and aiming to reach 1.875 billion[133]. Research and Development - Research and development expenses decreased by 31.26% to ¥40,992,447.18 compared to the previous year[5]. - The company's R&D investment amounted to 6,707.27 million RMB, representing 8.77% of operating revenue and 4.59% of net assets[26]. - The average R&D investment in the same industry was 35,786.23 million RMB, with the company's R&D investment accounting for 10.84% of operating revenue and 6.96% of net assets during the reporting period[26]. - The company is focusing on technological innovation and cost reduction in existing products while seeking breakthroughs in new products[83]. - The company is focusing on developing new products in the raw material and formulation projects, with multiple new projects initiated in 2023[27]. - The company has 36 products currently under research, with multiple new products expected to enter the registration application stage in the next 3-5 years[83]. - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product efficacy and safety[136]. - The company has established six major engineering technology innovation platforms for the research and development of small molecule drugs, peptide drugs, and oligonucleotide drugs[56]. - The company has a professional research team composed of PhD, master's, and bachelor's degree holders, equipped with advanced R&D testing equipment including UPLC-MS and GC-MS[147]. Marketing and Sales - The company plans to expand its marketing network and strengthen customer relationships while penetrating markets in Europe, America, and Asia[38]. - Over 85% of the company's products were sold overseas during the reporting period, indicating a strong international market presence[64]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of the next fiscal year[133]. - A new strategic partnership was announced, expected to enhance distribution channels and increase sales by 15%[133]. - The company's marketing team utilizes various methods for market expansion, including global pharmaceutical exhibitions and customer visits[167]. Environmental and Safety Management - The company invested 2,874.48 million RMB in environmental protection in 2023, with plans to increase this investment in the future[41]. - The company is committed to improving its EHS management system to mitigate environmental and safety risks associated with its production processes[41]. - The company has established a standardized hazardous waste storage area with a total area of 380 m²[155]. - The company has implemented various wastewater and waste gas treatment processes, ensuring compliance with environmental standards[155][157]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[152]. - The company has undergone changes in its board of directors, with several independent directors being elected or replaced[160]. Governance and Compliance - The company emphasizes the importance of internal control and governance, ensuring compliance with relevant laws and regulations[65]. - The company has established a comprehensive and effective internal control system, ensuring all subsidiaries maintained effective internal controls without significant defects during the reporting period[127]. - The company received a standard unqualified opinion in its internal control audit report for 2023[151]. - The company has implemented corrective measures for identified management issues to continuously improve its internal control system[127]. - The company has a diverse board with members holding various positions in other companies, enhancing its strategic oversight capabilities[124]. Shareholder Returns - The company plans to distribute a cash dividend of RMB 2.20 per 10 shares for the 2023 fiscal year, totaling RMB 89.3629 million, subject to shareholder approval[92]. - The company has approved a three-year shareholder return plan for 2023-2025 during the shareholder meeting[1]. - The company has a cash dividend policy that stipulates a minimum of 20% of the distributable profit should be distributed in cash if conditions allow[116]. - The company declared a cash dividend of 2.20 RMB per 10 shares, totaling 89,362,900 RMB, which represents 30.88% of the net profit attributable to ordinary shareholders in the consolidated financial statements[96]. Operational Efficiency - The company is focusing on enhancing production efficiency and product quality stability through continuous optimization of existing leading products[56]. - The company aims to improve operational efficiency by 15% through the implementation of advanced manufacturing technologies[136]. - The company has implemented upgrades to its waste gas treatment facilities, improving operational efficiency and treatment effectiveness[177]. Financial Management - The net cash flow from financing activities for 2023 was ¥49,019,558.18, compared to a negative ¥14,914,942.10 in the previous period[149]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to ¥17,156,238[159]. - The company plans to issue convertible bonds to raise funds for future projects, with a feasibility analysis report approved by the board[141].
奥锐特:奥锐特药业股份有限公司会计师事务所选聘制度
2024-04-28 07:47
奥锐特药业股份有限公司 会计师事务所选聘制度 第一章 总 则 第一条 为规范奥锐特药业股份有限公司(以下简称"公司")选聘(含续 聘、改聘)会计师事务所行为,切实维护股东利益,提高财务信息质量,保证财 务信息的真实性和连续性,根据《国有企业、上市公司选聘会计师事务所管理办 法》的有关规定,结合公司实际情况,制定本制度。 第二条 本制度所称选聘会计师事务所,是指公司根据相关法律法规要求, 聘任会计师事务所对财务会计报告发表审计意见、出具审计报告的行为。公司聘 任会计师事务所从事除财务会计报告审计之外的其他法定审计业务的,可参照本 制度执行。 第三条 公司选聘(含聘用或解聘)会计师事务所,应当由董事会审计委员 会审议同意后,提交董事会审议,并由股东大会决定。公司不得在股东大会决定 聘请会计师事务所前开展审计业务。 第二章 会计师事务所执业质量要求 第四条 公司选聘的会计师事务所应当具备下列条件: (一)具备国家行业主管部门和中国证券监督管理委员会(以下简称"中国 证监会")规定的开展证券期货相关业务所需的执业资格; (二)具有固定的工作场所、健全的组织机构和完善的内部管理和控制制度; (三)熟悉国家有关财务会计方 ...
奥锐特:奥锐特药业股份有限公司2023年度独立董事述职报告(苏为科)
2024-04-28 07:47
一、独立董事的基本情况及独立性说明 (一)本人工作履历、专业背景以及兼职情况 作为公司的独立董事,本人拥有专业资质及能力,在从事的专业领域 积累了丰富的经验。本人个人工作履历、专业背景以及兼职情况如下: 本人苏为科,1961年出生,民革党员,博士研究生学历,2001年7月 至今任浙江工业大学教授,曾主持或负责完成国家重点研发计划、"973" 前沿、"十一五"科技支撑计划、重大国际合作等国家级项目10余项、省 部级项目20余项,已有30余项重大科技成果实现产业化。取得3·1类原料 药批件1个和新药临床批件2个。主编《医药中间体制备方法》(2001化工 出版社)1部,参编《Ball Milling Towards Green Synthesis Applications, Projects, Challenges. 》(The Royal Society of Chemistry. UK, 2015) 1部,发表SCI收录论文200余篇,授权发明专利100余件。获国家科技发明 二等奖1项,省部级科技成果一等奖7项、中国专利优秀奖3项。荣获浙江 省特级专家,浙江省有突出贡献的专家称号,2014年获全国五一劳动奖状, ...
奥锐特:奥锐特药业股份有限公司关于会计政策变更的公告
2024-04-28 07:47
证券代码:605116 证券简称:奥锐特 公告编号:2024-021 奥锐特药业股份有限公司 关于会计政策变更的公告 本次变更前,公司执行的会计政策按财政部发布的《企业会计准则——基本 准则》和各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告以 及其他相关规定执行。 重要内容提示: 本次会计政策变更,是奥锐特药业股份有限公司(以下简称"公司")根 据财政部相关规定和要求进行的变更,符合相关法律法规的规定,执行变更后的 会计政策能够客观、公允地反映公司的财务状况和经营成果。本次会计政策变更 不会对公司当期的财务状况、经营成果和现金流量产生重大影响,不存在损害公 司及股东特别是中小股东利益的情况。 公司于 2024 年 4 月 25 日分别召开了第三届董事会第六次会议和第三届监事 会第六次会议,审议通过了《关于公司会计政策变更的议案》,公司本次会计政 策变更事项无需提交股东大会审议。具体情况如下: 一、本次会计政策变更概述 1、会计政策变更的原因 2022 年 11 月 30 日,财政部发布了准则解释第 16 号"关于单项交易产生的 资产和负债相关的递延所得税不适用初始确认豁免的会计处理",规定对于不 ...
奥锐特:奥锐特药业股份有限公司非经营性资金占用及其他关联资金往来情况的专项审计说明
2024-04-28 07:47
目 录 一、非经营性资金占用及其他关联资金往来情况的专项 审计说明…………………………………………………………第 1—2 页 二、非经营性资金占用及其他关联资金往来情况汇总表…………第 3—3 页 非经营性资金占用及其他关联资金往来情况的 专项审计说明 天健审〔2024〕3926 号 奥锐特药业股份有限公司全体股东: 我们接受委托,审计了奥锐特药业股份有限公司(以下简称奥锐特公司)2023 年度财务报表,包括 2023 年 12 月 31 日的合并及母公司资产负债表,2023 年度 的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所有者权益变 动表,以及财务报表附注,并出具了审计报告。在此基础上,我们审计了后附的 奥锐特公司管理层编制的 2023 年度《非经营性资金占用及其他关联资金往来情 况汇总表》(以下简称汇总表)。 二、管理层的责任 奥锐特公司管理层的责任是提供真实、合法、完整的相关资料,按照《上市 公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》(证监会公 告〔2022〕26 号)和《上海证券交易所上市公司自律监管指南第 2 号——业务 办理(2023 年 12 月修订)》( ...
奥锐特:奥锐特药业股份有限公司2023年度独立董事述职报告(刘凤珍已离任)
2024-04-28 07:47
奥锐特药业股份有限公司 2023 年度独立董事述职报告 (刘凤珍) 作为奥锐特药业股份有限公司(以下简称"公司")的独立董事,本人 严格按照《公司法》《证券法》《上海证券交易所上市公司自律监管指引 第 1 号——规范运作》《上市公司治理准则》等有关法律法规、规范性文 件及公司《章程》《独立董事工作细则》的规定和要求,报告期内(指 2023 年 1 月 1 日至 2023 年 5 月 4 日本人担任公司独立董事期间,下同), 本人凭借丰富的专业知识和经验,积极参加公司董事会及各专门委员会会 议、股东大会,在董事会日常工作及决策中尽职尽责,对董事会审议的重 大事项发表了独立客观的意见,为董事会的科学决策提供支撑,促进公司 规范运作,有效保障全体股东权益不受损害。 本人因任期届满于2023年5月5日公司召开2022年年度股东大会选举 产生新任独立董事后正式离任,不再担任公司董事会独立董事及各专门委 员会中相关职务。现将本人2023年度履行独立董事职责情况汇报如下: 一、独立董事的基本情况及独立性说明 (一)本人工作履历、专业背景以及兼职情况 作为公司的独立董事,本人拥有专业资质及能力,在从事的专业领域 积累了丰富的 ...
奥锐特:奥锐特药业股份有限公司关于续聘公司2024年度审计机构的公告
2024-04-28 07:47
证券代码:605116 证券简称:奥锐特 公告编号:2024-019 奥锐特药业股份有限公司 关于续聘公司 2024 年度审计机构的公告 2.投资者保护能力 重要内容提示: 一、拟聘任会计师事务所的基本情况 (一)机构信息 1.基本信息 | 事务所名称 | 天健会计师事务所(特殊普通合伙) | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 成立日期 | 2011 7 日 组织形式 | 年 | 月 | 18 | | 特殊普通合伙 | | 注册地址 | 浙江省杭州市西湖区西溪路 128 号 | | | | | | | 首席合伙人 | 王国海 上年末合伙人数量 | | | | | 238 人 | | 上年末执业人 | 注册会计师人数 | | | | | 2,272 人 | | 员数量 | 签署过证券服务业务审计报告的注册会计师人数 | | | | | 836 人 | | | 收入总额 34.83 亿元 | | | | | | | 2023 年度经审 计的财务数据 | 审计业务收入 30.99 亿元 | | | | | | | 情况 | | | | | ...
奥锐特(605116) - 2024 Q1 - 季度财报
2024-04-28 07:44
Financial Performance - The company's operating revenue for Q1 2024 was ¥335,623,155.40, representing an increase of 11.08% compared to the same period last year[11]. - The net profit attributable to shareholders for Q1 2024 was ¥82,184,172.26, showing a significant increase of 79.14% year-on-year[11]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥82,167,819.58, up by 87.43% compared to the previous year[11]. - The basic earnings per share for Q1 2024 was ¥0.20, which is an increase of 81.82% compared to the same period last year[11]. - The net profit for the first quarter of 2024 was CNY 82,184,172.26, an increase of 79.6% compared to CNY 45,710,870.38 in the same period of 2023[26]. - Operating profit reached CNY 100,448,940.91, up from CNY 58,973,162.21, reflecting a growth of 70.4% year-over-year[26]. - Total comprehensive income for the period was CNY 82,218,604.23, compared to CNY 45,499,843.26, reflecting a growth of 80.7%[29]. - Net profit attributable to shareholders increased by 79.14% due to higher sales[34]. - Net profit attributable to shareholders after deducting non-recurring gains and losses rose by 87.43% driven by increased sales[34]. - Basic and diluted earnings per share both increased by 81.82% as a result of net profit growth[34]. Cash Flow and Investments - The net cash flow from operating activities for Q1 2024 was ¥89,426,909.65, reflecting an increase of 11.98% year-on-year[11]. - Operating cash inflow totaled $384,208,482.52, an increase from $322,269,254.53 in the previous period, reflecting a growth of approximately 19.2%[52]. - Operating cash outflow amounted to $294,781,572.87, compared to $242,410,157.22 previously, indicating an increase of about 21.6%[52]. - Net cash flow from operating activities was $89,426,909.65, up from $79,859,097.31, representing a growth of around 6.5%[52]. - Cash inflow from investment activities was $539,851.53, significantly higher than $70,556.35 in the prior period[52]. - Cash outflow for investment activities reached $140,559,046.91, compared to $42,144,935.61 previously, showing a substantial increase[52]. - Net cash flow from investment activities was -$140,019,195.38, worsening from -$42,074,379.26 in the previous period[52]. - Cash inflow from financing activities was $134,514,228.46, a notable increase from $6,000,000.00[54]. - Net cash flow from financing activities was $32,322,871.92, compared to $4,752,760.27 previously, indicating a significant improvement[54]. - The impact of exchange rate changes on cash and cash equivalents was $4,520,030.30, up from $1,154,371.16[54]. - The ending balance of cash and cash equivalents was $400,661,672.44, a decrease from $414,411,055.95 at the beginning of the period[54]. Assets and Equity - The total assets at the end of Q1 2024 amounted to ¥2,687,167,606.86, a 4.37% increase from the end of the previous year[12]. - The equity attributable to shareholders at the end of Q1 2024 was ¥2,057,425,166.25, representing a 4.57% increase compared to the end of the previous year[12]. - The weighted average return on equity for Q1 2024 was 3.14%, an increase of 0.44 percentage points year-on-year[12]. - Non-current assets totaled ¥1,333,945,711.23, an increase from ¥1,208,569,413.41[42]. - Total assets amounted to ¥2,687,167,606.86, compared to ¥2,574,610,570.52 in the previous period[42]. Expenses and Liabilities - The company's cash and cash equivalents at the end of Q1 2024 were ¥533,570,045.96, down from ¥545,837,457.78 at the end of the previous year[20]. - The company's inventory at the end of Q1 2024 was ¥513,929,176.51, slightly up from ¥509,799,965.68 at the end of the previous year[20]. - Research and development expenses increased to CNY 28,932,083.97, compared to CNY 25,717,254.75, marking a rise of 8.6%[26]. - The tax expense for the period was CNY 16,923,971.88, compared to CNY 13,033,708.26, which is an increase of 30.5%[26]. - The company recorded a financial expense of CNY -11,642,386.52, a significant decrease from CNY 3,532,298.47 in the previous year, indicating improved financial management[26]. - The company reported a decrease in employee compensation payable to ¥28,712,915.37 from ¥50,466,614.00[42]. Shareholder Information - The number of common shareholders at the end of the reporting period was 7,801[36]. - The largest shareholder, Zhejiang Tongben Investment Co., Ltd., holds 37.81% of shares[36].
奥锐特:奥锐特药业股份有限公司2023年度内部控制评价报告
2024-04-28 07:44
公司代码:605116 公司简称:奥锐特 奥锐特药业股份有限公司 2023 年度内部控制评价报告 奥锐特药业股份有限公司全体股东: 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求(以下简称企业内部 控制规范体系),结合本公司(以下简称公司)内部控制制度和评价办法,在内部控制日常监督和专项 监督的基础上,我们对公司2023年12月31日(内部控制评价报告基准日)的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定,建立健全和有效实施内部控制,评价其有效性,并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏,并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整,提 高经营效率和效果,促进实现发展战略。由于内部控制存在的固有局限性,故仅能为实现上述目标提供 合理保证。此外,由于情况的变化可能导致内 ...